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Abstract
Background: Preference weights for EQ-5D-3L based on visual analogue scale (VAS) has recently been developed 
in Iran. The aim of the current study was to compare performance of this value set against the UK VAS-based 
value set. 
Methods: The mean scores for all possible 243 health states were compared using Student t test. Absolute 
agreement and consistency were investigated using concordance correlation coefficient (CCC) and Bland-
Altman plot. Health gains for 29 403 possible transitions between pairs of EQ-5D-3L health states were compared. 
Responsiveness to change and discriminative ability across subgroups of health transitions were assessed. 
Results: The mean EQ-5D-3L scores were similar for two value sets (mean = 0.31, P = 1.00). For 36% of health 
states, the absolute differences were greater than 0.10. There were three pairwise logical inconsistencies in the 
Iranian value set. The Iranian scores were lower (higher) for severe (mild) health states than the United Kingdom. 
The CCC (95% CI) was 0.85 (0.81 to 0.88) and Bland-Altman plot showed good agreement. The mean health gain 
for all possible transitions predicted by the Iranian value set was higher (0.22 vs. 0.20, P < .001) and two value sets 
predicted opposite transitions in 15% of transitions. The responsiveness of these two value sets were similar with 
lower discriminative ability for Iranian value set. 
Conclusion: The Iranian value set attribute lower values to most severe health states and higher values to mild 
health states compared with the UK value set. Such systematic differences might translate into discrepant health 
gains and cost-effectiveness which should be taking into account for informed decision-making. 
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Implications for policy makers
• While the Iranian and UK value sets provide comparable mean EQ-5D-3L index scores and good agreement, there were systematic differences 
between two value sets.
• Predicting lower values for most severe health states and higher values for mild health states by Iranian value set would result in higher health 
gain and more favourable cost-effectiveness results for quality of life improving interventions compared with the UK value set. 
• Moving from “no problems” to “some problems” on EQ-5D-3L dimensions had more relative importance for the Iranian respondents compared 
with the UK respondents while the opposite was observed for moving from “some problems” to “extreme problems.”
• Health authorities should be aware of the potential impact of different value sets on cost-effectiveness analyses, especially since it is probable 
that healthcare supplier applies a value set which supports their products. 
Implications for the public
Comparing the Iranian- and UK-VAS based EQ-5D-3L index scores showed that there were systematic differences between these two value sets 
implying that the UK value set might not be applicable for the Iranian population. However, due to possible sample selection bias, the presence of 
logical inconsistencies, and low know-group validity for health transitions, it is suggested that the Iranian value set should be applied with caution.
Key Messages 
Introduction
The EQ-5D-3L is a widely used generic preference-based 
measure to elicit health state utility values for use in cost-
utility analyses. It comprises five dimensions: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/
depression. Each dimension has 3 levels: no problems, some 
problems, extreme problems; resulting in 243 (35) possible 
health states.1 Each health state is assigned an index score by 
applying a value set elicited from general population or from 
patients. 
There are several valuation techniques to elicit value sets 
including time trade-off (TTO), standard gamble (SG), visual 
analogue scale (VAS), person trade-off, and more recently 
discrete choice experiment (DCE).2,3 Among these, the TTO 
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and VAS techniques have commonly been applied to develop 
the EQ-5D-3L value sets in several countries, especially in 
Europe.4 It should be noted that while VAS is considered as 
the most feasible valuation techniques, its choice-less nature 
raise concerns on its ability to elicit strength of preference for 
health states.5 In countries with no national value set, using a 
value set based on geographic proximity has been suggested4 
(the UK value set6 is the most common in Iran). However, 
regardless of techniques used to elicit value sets, it has been 
shown that there might be substantial differences in values 
across countries and hence developing local value sets have 
been recommended.7-11 In Iran, a VAS-based value set for 
EQ-5D-3L has recently developed.12 The current study aimed 
to compare the EQ-5D-3L index scores from this newly 
developed value set12 with the UK VAS-base value set.13 The 
results of this study might be of interest to policy-makers 
in Iran and other developing countries who make decisions 
on transferring value set from developed countries to their 
population and its potential impact on economic evaluations. 
Methods 
The EQ-5D-3L Value Sets
The UK VAS-based value set13 is based on transformed VAS-
based values for 42 EQ-5D-3L health states measured from 
2997 eligible respondents (the mean ± standard deviation 
[SD] age of 47.1 ± 18.1 years, 57% were women, and 31% 
were current smokers) from the UK general population. The 
mean absolute difference between observed and the predicted 
values for these 42 health states was 0.041, with the maximum 
absolute difference of 0.086. This model include 10 main effect 
terms, the constant term (a dummy variable if any dimension 
is at either level 2 or level 3 to capture any deviation from full 
health), and N3 term (a dummy variable if any dimension is 
at level 3). 
The Iranian VAS-based value set12 is based on transformed 
VAS-based values for the same 42 EQ-5D-3L health states 
as the UK study13 measured from 853 respondents (the 
mean ± SD age of 38.2 ± 14.7 years, 45% were women, and 
14% were current smokers) from city of Tehran (the capital of 
Iran). The mean absolute difference between observed and the 
predicted values for these 42 health states was 0.074, with the 
maximum absolute difference of 0.216.12 This model includes 
10 main effect terms, the constant term, and I3-squared term 
(square of number of dimensions at level 3 beyond the first). 
Statistical Analysis
The Iran12 and UK13 VAS-based EQ-5D-3L index scores for 
all 243 EQ-5D-3L health states were calculated. Two value 
sets were compared using Student t test, Wilcoxon rank-sum 
test, and Spearman rank correlation. Agreement between 
these value sets was evaluated using Bland-Altman plots14 
and concordance correlation coefficient (CCC) proposed by 
Lin.15 The presence of logical inconsistency (ie, predicting a 
higher value for a logically worse health state than a logically 
better health state) was examined. A health state is considered 
logically better than another health state if it has better status 
on at least one dimension with no worse status on any other 
dimension.16 Two value sets were compared across five 
quintiles of health states defined based on the Iranian EQ-
5D-3L index scores (from most to least severe health states). 
The absolute transition scores in the EQ-5D-3L index scores 
for 29 403 (2C243) pairs of EQ-5D health states were compared 
using Student t test. An absolute transition score measures 
the health utility change for a transition from a worse health 
state to a better health state.17 In addition, the responsiveness 
of two value sets across consistent health transition (ie, 
transitions that yield health gain in both value sets) was 
assessed by assuming the health state with lower value as 
pre-treatment and the health state with higher value as post-
treatment and computing standardized response mean.17 
Moreover, four possible changes across three levels of EQ-5D-
3L were defined: (i) major improvement: changes from level 
3 to level 1 or 2; (ii) minor improvement: changes from level 
2 to level 1; (iii) minor deterioration: changes from level 1 to 
level 2; and (iv) major deterioration: changes from level 1 or 
2 to level 3. Based on these changes, six mutually exclusive 
subgroups were defined: (1) major improvement with no 
deterioration, (2) minor improvement with no deterioration, 
(3) major improvement with minor deterioration, (4) 
major improvement with major deterioration, (5) minor 
improvement with minor deterioration, and (6) minor 
improvement with major deterioration. It should be noted that 
a transition including both major and minor improvement 
(deterioration) is considered only as a major improvement 
(deterioration). In addition, based on the expected health 
gain for these subgroup, eleven pairwise comparisons were 
formed and the discriminative ability of two value sets for 
these pairwise comparisons was assessed by calculating the 
effect size (the difference between the mean of two subgroups 
divided by the pooled standard deviation18). Due to high 
number of statistical tests, all P values were corrected using 
Bonferroni correction. 
Results
The mean (SD) of the EQ-5D-3L index score predicted by the 
Iranian and UK value sets were 0.31 (0.20) and 0.31 (0.18), 
Table 1. The EQ-5D-3L Index Scores and Absolute Transition Scores Predicted by the Iranian and UK VAS Value Sets
n Mean SD Median Minimum Maximum 
EQ-5D-3L index score
Iran 243 0.31 0.20 0.30 − 0.09 1.00
UK 243 0.31 0.18 0.28 − 0.07 1.00
Iran–UK 243 − 0.00 0.11 − 0.01 − 0.30 0.29
Absolute transitions scores (all transitions)
Iran 29 403 0.22 0.17 0.00 1.09
UK 29 403 0.20 0.17 0.00 1.07
Iran–UK 29 403 0.02 0.13 − 0.44 0.48
Abbreviation: VAS, visual analogue scale.
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respectively (Table 1). There were no statistically significant 
differences in the mean and median of scores predicted by 
two value sets (P = 1.00 for mean and median). Spearman 
rank correlation between two value sets was 0.87 (P < .001). 
The Iranian value set had a slightly wider range than the UK 
value set (from −0.09 to 1.00 vs. −0.07 to 1.00, Figure 1). Both 
value sets attributed a value of 1.00 to health state 11 111. The 
Iranian value set predicted a lower index score for 129 health 
states. There were 241 and 187 health states with unique index 
score in the Iranian and UK value sets, respectively. 
The second best health state was “21 111” (index score = 0.80) 
in the Iranian value set and “11 211” (index score = 0.81) 
in the UK value set. There were more health states with a 
negative index scores in the Iranian than UK value set (14 vs. 
4). The predicted scores by the Iranian value set for health 
states 32 333 (−0.09), 23 333 (−0.08), and 22 333 (−0.07) was 
lower than health state 33 333 (−0.07) implying the presence 
of three pairwise logical inconsistencies. 
Across five quintiles of EQ-5D-3L health states, the Iranian 
value set predicted statistically significantly lower scores 
for most severe health states and higher scores for least 
severe health states (Table 2 and Figure 2). The magnitude 
of absolute difference was higher for mild health states. The 
Bland-Altman plots (Figure 3) showed that there was a good 
Figure 1. Distribution of EQ-5D-3L VAS-Based Index Scores Predicted by 
the Iranian and UK Value Sets. Abbreviation: VAS, visual analogue scale.
Figure 3. Bland-Altman Plots of EQ-5D-3L VAS-Based Index Scores 
Predicted by the Iranian and UK Value Sets.  Abbreviation: VAS, visual 
analogue scale.
Figure 2. The EQ-5D-3L VAS-Based Index Scores for 243 EQ-5D-3L 
Health States Predicted by the Iranian and UK Value Sets. Abbreviation: 
VAS, visual analogue scale.
agreement between two value sets and more than 96% of the 
differences in EQ-5D-3L index scores fell within the 95% 
limits of agreement. Agreement between two value sets was 
good with a CCC (95% CI) of 0.85 (0.81 to 0.88).
The mean absolute transition scores for the 29 403 the EQ-
5D-3L heath transitions were 0.22 and 0.20 using the Iranian 
and UK value sets, respectively (mean difference = 0.02, 95% 
CI: 0.02 to 0.03). In 24 884 (85%) of 29 403 health transitions, 
both value sets were consistent in predicting health gain/loss. 
In about 60% of consistent health transitions, the Iranian value 
set predicted a higher health gain than the United Kingdom 
with an absolute difference in predicted health gain greater 
than 0.10 (0.25) in about 46% (7%) of these transitions. 
There was a statistically significant difference in health gain 
predicted by two value sets for consistent health transitions 
(mean difference = 0.03, P < .001) with more profound 
differences within subgroups of transition (mean difference 
ranged 0.02 to 0.11, P < .001 for all comparisons, Table 3). In 
all subgroups but “major improvement, minor deterioration” 
the Iranian value set predicted a higher health gain and had 
higher responsiveness to change compared with the UK value 
set.
The Iranian value set had generally lower discriminative 
ability than the UK value set (Table 4) and was not able to 
discriminate between minor and major deteriorations when 
the level of improvement was the same (eg, the same health 
gain for “major improvement with minor deterioration” and 
“major improvement with major deterioration” while a higher 
health gain from first subgroup is expected). 
Discussion 
In the current study, the recently developed Iranian VAS-based 
EQ-5D-3L valuation was compared with the corresponding 
valuation in the United Kingdom. The results showed that 
while there was good overall agreement between two value 
sets, there were evidence of systematic differences. The 
Iranian value set predicted lower values for most severe health 
states and higher values for mild health states. This systematic 
difference resulted in a higher health gain predicted by the 
Iranian value set compared with the UK value set and this was 
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more profound for transitions comprise minor improvement 
with no deterioration. 
The higher health gain predicted by the Iranian value set 
would translate into lower and more favourable incremental 
cost-effectiveness ratios (ICERs) compared with the UK value 
set. Of course, in 10 083 (41%) of 24 884 consistent health 
transitions, the UK value set would result in higher health gain 
and in turn lower ICERs compared with the Iranian value set. 
Furthermore, in about 15% of health transitions, two value 
sets would give completely different results on health gain (ie, 
for the same transition while one value set predicted a health 
gain, the other value set predicted a health loss). This figure 
was about 6% in comparison of the UK and US TTO-based 
value sets.17 
Whether different ICERs produced by two value sets translate 
into discrepant decision funding depends on several factors 
including the distribution of health transitions in the sample 
under study, efficacies of interventions, the severity of the 
health condition under study, cost differences between 
interventions, and willingness to pay (WTP) threshold.19 For 
example, if health transitions with negligible differences in 
health gains are more common in a study, then the choice of 
value set does not influence the estimated ICER. However, 
if health transitions with substantial differences in health 
gain are prevalent in a study, then estimated ICER might 
result in discrepant decisions. This has important policy 
implications as applying different value sets might generate 
different results from economic evaluation studies and in turn 
different decision by policy-makers. Therefore, the impact of 
the choice of EQ-5D value set on ICERs should be assessed 
through sensitivity analyses and should be reported to health 
authorities by healthcare suppliers to aid informed decision-
making. In addition, previous healthcare interventions that 
had been found cost-effective using the UK tariff might not 
be cost-effective with the Iranian tariff and vice versa.
Interestingly, on all EQ-5D-3L dimensions, (1) a moving 
from level 1 or 2 to level 3 was associated with higher utility 
decrement in the UK value set than the Iranian value set, 
and (2) a moving from level 1 to level 2 had a higher utility 
decrement than moving from level 2 to level 3 in the Iranian 
value set, while opposite was observed in the UK value set. 
Although, the presence of N3 term in the UK value set might 
seems as an explanation, the similar differences was found 
in the N3 model specification of the Iranian value set.12 In 
addition, the self-care and anxiety/depression were most 
important and mobility was least important dimensions of the 
EQ-5D-3L in the Iranian valuation, while pain and mobility 
were most important and usual activity was least important 
dimensions in the UK valuation. These differences might 
influence the priority given to interventions and should be 
taking into account by policy-makers. For example, if an 
intervention influence mainly the mobility dimension of EQ-
5D-3L, then priority given to this intervention depends on the 
value set used (high priority based on the UK value set and 
low priority base on the Iranian value set). There are several 
potential explanations for the observed differences between 
two value sets including inherent differences between two 
populations (eg, cultural differences) that influenced their 
valuation, difference in methodologies used to develop value 
sets, difference induced by translation, time effects (the 
Iranian value set was recently developed while the UK value 
set developed in 1995), and difference in response style.9,20,21
While application of a national value set is generally 
supported,4 the Iranian value set suffer from several 
limitations that call for caution in its application. The Iranian 
valuation study12 was conducted in the capital city of Iran with 
specific health–cultural–socio-economic status which might 
not be representative of the Iranian general population (eg, 
highly educated participants of whom 42% had academic 
education and solely from urban areas). A recent systematic 
review22 showed that education, urbanisation, and healthcare 
expenditure are associated with utilities attributed to the 
EQ-5D-3L valuations indicating that the generalizability of 
the Iranian value set might be limited. In addition, it is not 
clear on what grounds the final model for the Iranian value 
set12 has been selected. For example, the authors12 stated that 
“all models were tested and compared regarding the number 
of incoherent coefficients, the statistical significance of the 
coefficients, the amount of explained variance (R2), the mean 
absolute error (MAE), and the Akaike information criterion 
(AIC).” However, the final model did not outperform other 
specifications based on any of these criteria. Furthermore, the 
Iranian value set had low discriminative ability to distinguish 
minor deterioration from major deterioration, and the 
model12 was not validated in an internal or external sample. 
The results of the current study should be interpreted in light 
of several limitations. Due to a lack of data on changes in 
health status over time, the same probability of occurrence for 
all health transitions was assumed that is not true in reality. 
This implies that the results might be different compared 
to clinical studies where a small subgroup of the EQ-5D-3L 
health states are present. In addition, a lack of data avoids 
assessing test-retest reliability of two value sets. Comparing 
these value sets in longitudinal empirical studies can overcome 
these limitations. 
Conclusion
While the Iranian and UK value sets provide comparable 
mean EQ-5D-3L index scores and good agreement, there 
are systematic differences between two value sets. The 
Iranian value set attribute lower values for most severe health 
states and higher values for mild health states than the UK 
Table 2. The EQ-5D-3L Index Scores Across Five Quintile of Health States Ranked by The Iranian Value Set
Iran, Mean UK, Mean Mean Difference (95% CI) Mean Absolute Difference
Most severe health states (n = 49) 0.05 0.12 −0.07 (−0.09 to −0.05) 0.08 (0.07 to 0.10)
Q2 (n = 49) 0.19 0.22 −0.03 (−0.05 to −0.01) 0.06 (0.04 to 0.07)
Q3 (n = 48) 0.30 0.29 0.00 (−0.02 to 0.03) 0.07 (0.05 to 0.09)
Q4 (n = 49) 0.41 0.38 0.03 (−0.00 to 0.06) 0.09 (0.07 to 0.11)
Least severe health states (n = 49) 0.60 0.55 0.05 (0.01 to 0.09) 0.12 (0.10 to 0.14)
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Table 3. Responsiveness of EQ-5D-3L Index Scores Predicted by the UK and Iranian Value Sets Across Consistent Health Transitions
All Consistent 
Transitions (n = 24 884)
Major Improvement, no 
Deterioration (n = 6749) a
Minor Improvement, no 
Deterioration (n = 781) b
Major Improvement, Minor 
Deterioration (n = 4969) c
Major Improvement, Major 
Deterioration (n = 11 407)d
Minor Improvement, Minor 
Deterioration (n = 509) e
Minor Improvement, Major 
Deterioration (n = 469) f 
Iran UK Iran UK Iran UK Iran UK Iran UK Iran UK Iran UK
Pre-treatment EQ-5D-3L index score 0.18 0.20 0.12 0.15 0.27 0.34 0.26 0.24 0.17 0.19 0.38 0.45 0.19 0.24
Post-treatment EQ-5D-3L index score 0.43 0.42 0.49 0.50 0.50 0.46 0.47 0.53 0.38 0.33 0.51 0.52 0.32 0.29
Health gain 0.25 0.22 0.37 0.35 0.23 0.12 0.21 0.29 0.21 0.13 0.13 0.07 0.13 0.05
Standardized response mean 1.49 1.31 2.04 1.92 1.92 1.66 1.49 1.93 1.49 1.47 1.42 1.33 1.41 1.23
a At least one change from level 3 to level 1 or 2, with no deterioration; b At least one change from level 2 to level 1, with no deterioration; c At least one change from level 3 to level 1 or 2, with at least one change from level 1 to level 2; d At 
least one change from level 3 to level 1 or 2, with at least one change from level 1 or 2 to level 3; e At least one change from level 2 to level 1, with at least one change from level 1 to level 2; f At least one change from level 2 to level 1, with 
at least one change from level 1 or 2 to level 3.
Table 4. Discriminative Ability of the Iranian and UK Value Sets Across Combinations of Health Transitions
Iran Value Set UK Value Set
Mean Difference P Effect Size Mean Difference P Effect Size
“Major improvement, no deterioration” vs. “minor improvement, no deterioration” 0.14 < .001 0.76 0.24 < .001 1.24
“Major improvement, no deterioration” vs. “major improvement, minor deterioration” 0.16 < .001 0.88 0.06 < .001 0.34
“Major improvement, no deterioration” vs. “major improvement, major deterioration” 0.16 < .001 0.93 0.22 < .001 1.29
“Major improvement, no deterioration” vs. “minor improvement, minor deterioration” 0.24 < .001 1.27 0.29 < .001 1.49
“Major improvement, no deterioration” vs. “minor improvement, major deterioration” 0.24 < .001 1.28 0.31 < .001 1.58
“Minor improvement, no deterioration” vs. “minor improvement, minor deterioration” 0.10 < .001 0.82 0.05 < .001 0.77
“Minor improvement, no deterioration” vs. “minor improvement, major deterioration” 0.10 < .001 0.83 0.07 < .001 1.02
“Major improvement, minor deterioration” vs. “major improvement, major deterioration” 0.00 1.00 0.01 0.16 < .001 1.19
“Major improvement, minor deterioration” vs. “minor improvement, minor deterioration” 0.07 < .001 0.55 0.23 < .001 1.42
“Major improvement, minor deterioration” vs. “minor improvement, major deterioration” 0.08 < .001 0.55 0.25 < .001 1.53
“Major improvement, major deterioration” vs. “Minor improvement, major deterioration” 0.08 < .001 0.55 0.09 < .001 0.96
“Minor improvement, minor deterioration” vs. “Minor improvement, major deterioration” 0.00 1.00 0.01 0.02 < .001 0.41
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value set. Such systematic differences might translate into 
discrepant health gains and ICERs which have important 
policy implications. Moving from level 1 to level 2 of EQ-
5D-3L dimensions had more relative importance for the 
Iranian respondents compared with the UK respondents. The 
presence of several significant limitations in the Iranian value 
set including possible sample selection bias and presence of 
logical inconsistencies implies that it should be applied with 
caution. In particular, due to logical inconsistency the use of 
the Iranian value set in samples with severe EQ-5D-3L health 
states is not recommended. Developing a new value set in Iran 
using a large representative national survey with a transparent 
methodology is highly recommended. 
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